肺癌 (LC) 是全球癌症相关死亡的主要原因，非小细胞肺癌 (NSCLC) 占到80%以上。关于年龄对 NSCLC 临床结果的影响仍然不明确，尤其是免疫反应方面。在本研究中，我们使用人类衰老基因组资源中与人类衰老相关的 307 个基因，探讨了年龄对 NSCLC 的影响。我们鉴定出 53 个与 NSCLC 患者总生存显著相关的衰老相关基因，其中包括临床验证的基因 BUB1B。此外，我们开发了一个与年龄相关的富集分数，根据患者的衰老亚型对其进行分类，并评估它们在 LC 中的预后和治疗反应价值。我们的分析得到了两个与衰老相关的亚型，其在肿瘤微环境中具有独特的特征，表明对免疫治疗的不同反应。基于转录组文件的一致性聚类提供了关于衰老对 NSCLC 的影响的见解，并突出了个体化治疗方法在衰老亚型上的潜力。我们的发现为 NSCLC 患者个体化治疗方法提供了新的靶点和理论支持，揭示了年龄对癌症结果的潜在影响。© 2023 国际生物化学与分子生物学联合会。

Lung cancer (LC) is a leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 80% of cases. The impact of aging on clinical outcomes in NSCLC remains poorly understood, particularly with respect to the immune response. In this study, we explored the effects of aging on NSCLC using 307 genes associated with human aging from the Human Ageing Genomic Resources. We identified 53 aging-associated genes that significantly correlate with overall survival of NSCLC patients, including the clinically validated gene BUB1B. Furthermore, we developed an aging-associated enrichment score to categorize patients based on their aging subtypes and evaluated their prognostic and therapeutic response values in LC. Our analyses yielded two aging-associated subtypes with unique profiles in the tumor microenvironment, demonstrating varying responses to immunotherapy. Consensus clustering based on transcriptome profiles provided insights into the effects of aging on NSCLC and highlighted the potential of personalized therapeutic approaches tailored to aging subtypes. Our findings provide a new target and theoretical support for personalized therapeutic approaches in patients with NSCLC, offering insights into the potential impact of aging on cancer outcomes.© 2023 International Union of Biochemistry and Molecular Biology.